Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine, a Canada-based developer of vaccines for cancer therapy, has named John Trizzino as the CEO, effective 1 October 2011.
Subscribe to our email newsletter
Most recently, Trizzino worked for Novavax as the senior vice president.
Prior to joining Novavax, he held senior executive positions at MedImmune acquired by AstraZeneca, and ID BioMedical, now part of GlaxoSmithKline.
Immunovaccine chairman Albert Scardino said as their development program accelerates with a second cancer vaccine in the clinic, they are pleased to be joined by someone with John’s experience in partnering, licensing and distribution.